Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

The carcinoembryonic antigen glypican-3 (GPC3) is a good target of anticancer immunotherapy against pediatric solid tumors expressing GPC3. In this non-randomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3-peptide vaccination in patients with pediatric solid tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Nobuhiro, Hosono, Ako, Yoshikawa, Toshiaki, Shoda, Kayoko, Nosaka, Kazuto, Shimomura, Manami, Hara, Junichi, Nitani, Chika, Manabe, Atsushi, Yoshihara, Hiroki, Hosoya, Yosuke, Kaneda, Hide, Kinoshita, Yoshiaki, Kohashi, Kenichi, Yoshimura, Kenichi, Fujinami, Norihiro, Saito, Keigo, Mizuno, Shoichi, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739579/
https://www.ncbi.nlm.nih.gov/pubmed/29296538
http://dx.doi.org/10.1080/2162402X.2017.1377872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739579/
https://www.ncbi.nlm.nih.gov/pubmed/29296538
http://dx.doi.org/10.1080/2162402X.2017.1377872

Ejemplares similares